PS
PeptideScholar

Content reviewed by clinical research staff

Last reviewed: March 2026Sources: PubMed, FDA, WADA Prohibited List

Evidence graded using the PeptideScholar A-D system

Sermorelin

AFDA Approved

GHRH analog · 29 amino acids · Brand: Geref

FDA ApprovedPrescription RequiredWADA Banned

Sermorelin is the shortest fully functional fragment of GHRH (amino acids 1-29). It was the first GHRH analog approved by the FDA, marketed as Geref for diagnostic and therapeutic use.

Mechanism of Action

Binds GHRH receptors on anterior pituitary somatotrophs, stimulating natural pulsatile GH release. Preserves the physiological GH feedback axis.

Benefits

  • FDA-approved track record for GH stimulation
  • Preserves natural GH pulsatility
  • Improved body composition in clinical studies
  • Enhanced sleep quality
Not Medical Advice — Research-Reported Information Only

This content is for informational purposes only and does not constitute medical advice.

Sermorelin — Dosing in Published Research

Reported Routes: Subcutaneous injection
FDA-approved dosing was 0.03 mg/kg SC at bedtime for pediatric GH deficiency. Compounded versions used 200-300 mcg SC nightly.

The dosing information above is sourced from published research literature and clinical trials. These are not recommendations. Individual responses vary. Always consult a healthcare provider before considering any peptide-based therapy.

Side Effects

  • Pain at injection site
  • Flushing
  • Headache
  • Dizziness
  • Swelling or urticaria

Ready to Discuss Sermorelin with a Doctor?

Sermorelin is FDA-approved and available by prescription. Licensed telehealth providers can evaluate if it's right for you.

Find a Prescribing Provider

Telehealth consultations available in most states

FDA ApprovedBoard-Certified DoctorsPrescription if Appropriate

PeptideScholar may receive compensation from provider referrals. This does not influence our editorial content.

Research & Evidence

RCTJournal of Pediatric Endocrinology, 1998

Sermorelin treatment of growth hormone deficiency in children

Sermorelin produced clinically meaningful growth acceleration in GH-deficient children

PMID: 9467542
CohortEndocrine, 1999

Long-term effects of sermorelin acetate in adults

Six months of sermorelin improved lean body mass and reduced body fat in adults with GH insufficiency

PMID: 10352397

Compare Sermorelin With

Sermorelin vs Ipamorelin
Sermorelin vs CJC-1295
Sermorelin vs Tesamorelin
Sermorelin vs Semaglutide
Sermorelin vs GHRP-2
Sermorelin vs GHRP-6
Sermorelin vs Hexarelin

References

  1. 1. Sermorelin treatment of growth hormone deficiency in children. Journal of Pediatric Endocrinology, 1998. “Sermorelin produced clinically meaningful growth acceleration in GH-deficient children” [PMID: 9467542]
  2. 2. Long-term effects of sermorelin acetate in adults. Endocrine, 1999. “Six months of sermorelin improved lean body mass and reduced body fat in adults with GH insufficiency” [PMID: 10352397]

Recommended Resources

The Peptide Protocols Handbook

Evidence-based reference guide covering mechanisms, research, and clinical applications.

View on Amazon

Third-Party Peptide Testing

Independent lab analysis to verify peptide purity and authenticity.

Learn More

Links may be affiliate links. See our disclosure.

Medical Disclaimer

This content is for informational and educational purposes only and does not constitute medical advice, diagnosis, or treatment recommendations.

Always consult a qualified healthcare provider before starting, stopping, or modifying any treatment. Do not disregard professional medical advice based on information found on this site.

No claims of therapeutic efficacy are made for substances that are not FDA-approved for the discussed indications. Research citations reflect published findings and do not imply endorsement.

Get Peptide Research Updates

Weekly evidence summaries and regulatory alerts.

No spam. Unsubscribe anytime.